Introduction: Assessing the consequences of chronic spontaneous/idiopathic urticaria (CSU)
INTRODUCTION
In chronic spontaneous urticaria (CSU) or ''chronic idiopathic urticaria'', itchy hives (wheals), angioedema, or both, occur for 6 or more weeks [1] . Chronic urticaria is common [2] [3] [4] , impacting patients' health-related quality of life (HRQoL), their ability to perform daily tasks, and their mental health [1, 5, 6] .
CSU severity is assessed by evaluating signs
[hives (changing daily)] and symptoms (itch).
Patients count and record these using a daily diary such as the Urticaria Activity Score (UAS).
HRQoL impact is assessed using generic, dermatologic-specific, or urticaria-specific [7] patient-reported outcome measures (PROMs).
To gauge CSU treatment efficacy, clinicians must assess changes in the patient's condition.
Disease-specific HRQoL measures are more sensitive than generic ones in evaluating disease impact or detecting severity change or treatment response [8] and are more informative about CSU burden and changes in burden. Each PROM type provides different disease status information; sign measures do not provide HRQoL insights.
However, if different PROMs showed similar patterns over time after changes in disease, clinicians could make inferences about a patient based on one of them. It is valuable to assess the extent to which different PROMs provide similar information about changes in CSU and its effects on quality of life (QoL), giving clinicians options for understanding patient experience.
Signs and symptoms of CSU and HRQoL show moderate correlation [9] . These correlations were based on only one time point and so did not assess the strength of relationships between changes in signs and symptoms and HRQoL changes after treatment.
To We rejected traditional comparisons of change over time for the longitudinal modeling technique of latent growth modeling (LGM).
LGM calculates individual patient change trajectories across all time points simultaneously; this allows comparisons between changes in outcomes from multiple measures in a single analysis and can account for non-linear changes in the patient's condition. This technique was used to model cancer patients with anemia [10] , but has rarely been applied to clinical trial data and has not been used within dermatology.
The objective of this study was to use LGM to assess the extent to which changes in three PROM types-CSU signs and symptoms, dermatologic and urticaria-specific QoL-are related in their patterns of change. The LGM results were compared with a traditional piecewise approach.
METHODS

Data
Data were collected from three phase 3 trials of omalizumab in refractory CSU: ASTERIA I (40 weeks [11] ), ASTERIA II (28 weeks [12] ) and GLACIAL (40 weeks [13] ) (Fig. 1) This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Measures
Urticaria Activity Score (UAS) [15] [16] [17] The UAS is a self-completed daily diary measuring CSU signs (hives) and symptoms (pruritus). Patients record twice-daily number of hives using a 0-3 range (0 = no hives; 3 = 12 or more hives in 12 h). Patients also record twice-daily pruritus severity, using a 0-3 range (0 = none; 3 = severe). The average daily score for the combined hives and pruritus scores is summed across 7 days to create a weekly score (UAS7) ranging from 0 to 42; higher scores indicate greater severity. Each trial required a UAS7 score of at least 16 for inclusion.
The UAS7 was calculated weekly during the trials. For ASTERIA I and GLACIAL, scores were reported at baseline; at weeks 4, 8, 12, 16, and Dermatology Life Quality Index [18] [19] [20] The Dermatology Life Quality Index (DLQI) is a 10-item self-reported questionnaire with a 1-week recall designed to assess QoL in skin diseases. It is validated in CSU [19, 20] . Each item has four response categories, ranging from ''not at all'' (score = 0) to ''very much'' (score = 3). Individual item scores are summed to a total score (range 0-30); higher scores indicate worse QoL.
For ASTERIA I and GLACIAL, the DLQI was administered at baseline, at weeks 4 and 12 during treatment and at weeks 24 and 40 after treatment stopped. For ASTERIA II, the DLQI was administered at baseline, at weeks 4 and 12 during treatment, and at week 28 after treatment stopped. The DLQI has been validated for individuals aged 16 years and older: the analysis used data from this age range.
Chronic Urticaria Quality of Life (QoL)
Questionnaire [21] The Chronic Urticaria QoL Questionnaire
urticaria-specific measure evaluating physical, psychosocial, and practical aspects of QoL. It has a 2-week recall period and six-dimensions: pruritus, swelling, impact on life activities, sleep problems, limits, and looks. Each item has five response categories ranging from ''never'' to ''very much''. The total score ranges from 0 to 100; higher scores indicate worse QoL. The CU-Q 2 oL was administered at the same times as the DLQI in all trials. As the instrument was developed within populations aged 18 years and older, the analysis used data from this age range.
Statistical Analyses
Latent growth models (LGM) were applied to data from the three trials using information from every available time point.
LGM is a growth curve analysis based on structural LGMs can be conducted using ''full information maximum likelihood'', a method for handling missing data [23] . An adjustment of the overall variance-covariance matrix (using maximum likelihood estimation) is based on the data from complete cases.
LGMs automatically make use of information on all study participants, assuming data are missing at random. In contrast, traditional mean difference score analysis uses data only from patients with data at both time points, resulting 
RESULTS
Patients' characteristics at baseline were similar across each trial (Table 1) However, the correlation is 0.64 between baseline and week 4 and 0.48 between week 4 and week 12.
Figure 3a-c show the slopes of change in UAS7 and the CU-Q 2 oL scores for ASTERIA I, ASTERIA II, and GLACIAL. As with UAS7 and DLQI, the growth curves reflect the mean changes in UAS7 and CU-Q 2 oL for each trial and show a decrease in UAS7 and CU-Q 2 oL scores (CSU improvement) during treatment.
There was an increase in scores (CSU worsening) after treatment was discontinued. This pattern was similar for both the UAS7 and the CU-Q 2 oL. 
DISCUSSION
The LGM results showed a near-perfect association between changes in signs and symptoms and dermatologic QoL and changes in urticaria-specific QoL. These results, across and GLACIAL (c). DLQI Dermatology Life Quality Index, PRO patient-reported outcome, UAS7 Urticaria Activity Score over 7 days Table 2 Piecewise results for ASTERIA I: correlations in mean difference scores from baseline between the UAS7 and the DLQI Small-to-moderate relationships between the UAS7 and the DLQI [24] and between the UAS7 and the CU-Q 2 oL [25] were reported using simple correlation analyses, also seen in Table 2 . This piecewise approach based correlations on a single time point or comparing changes between two time points.
The LGM results go beyond this using individual patient-level information across all time points simultaneously. Previous studies had restricted inferences due to the aggregate focus of the analyses. The present study uses an individual patient-level focus: the intercepts and slopes of change for every patient across all time points are used for correlations, providing more accurate, comprehensive understanding of changes.
The assessment period for the UAS7 (daily but summed to 1 week) and the recall period for the CU-Q 2 oL (2 weeks) are different, yet the correlations between them were as large as those between the UAS7 and the DLQI (both 1 week). This suggests patients' HRQoL experiences of CSU are consistent and that different recall periods do not attenuate relationships among the PROMs.
Physicians have a choice of PROMs to assess the severity impact of CSU and treatment response. Clinicians can feel confident in using whichever measure is available and with whichever they are more familiar. If an improvement (or worsening) in signs and symptoms is found, it is highly likely that an improvement (or worsening) HRQoL is also experienced, and vice versa.
These results highlight the level of specificity and potential temporal ordering of HRQoL measures in CSU. Patient-reported symptoms are considered most ''proximal'' to treatment effects and the patient's experience, while HRQoL is more ''distal'' to symptoms and treatment effects [26] . A disease-specific PROM is likely to be more proximal to symptoms and treatment effects than a more general HRQoL PROM [26] . However, in this study changes in CSU signs and symptoms (that treatment directly affects) are highly correlated with changes in the generic or CSU specific QoL measures; knowing one of these dimensions yields a very good understanding of the other two-dimensions of the patients' experience of change.
One potential concern relates to the utilization of the DLQI and the CU-Q 2 oL. Some aspects of the psychometric properties of the DLQI have been criticized [27] ; however, the DLQI has been validated for use in CSU [19, 28, 29] and the minimally important difference determined [20] . The CU-Q 2 oL is a relatively recent addition to the study of HRQoL in CSU and is recommended for assessment of HRQoL by international guidelines [1] . Validation of any measure is a multi-facetted process and this analysis provides evidence of these measures meeting another aspect of validationthat they change together very closely.
A second concern is that the analyses were of trial results of an extremely effective treatment. 
